A Clinical Study of Curcuvail® in Patients With Non-alcoholic Fatty Liver Disease
Status:
COMPLETED
Trial end date:
2021-11-25
Target enrollment:
Participant gender:
Summary
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease. It comprises a wide spectrum of disorders that range from simple steatosis to nonalcoholic steatohepatitis (NASH), advanced fibrosis, related cirrhosis, and even hepatocellular carcinoma (HCC).